HomeCompareWCRS vs ABBV

WCRS vs ABBV: Dividend Comparison 2026

WCRS yields 0.58% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $77.4K in total portfolio value
10 years
WCRS
WCRS
● Live price
0.58%
Share price
$17.10
Annual div
$0.10
5Y div CAGR
33.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.9K
Annual income
$1,274.42
Full WCRS calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WCRS vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWCRSABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WCRS + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WCRS pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WCRS
Annual income on $10K today (after 15% tax)
$49.71/yr
After 10yr DRIP, annual income (after tax)
$1,083.26/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $19,972.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WCRS + ABBV for your $10,000?

WCRS: 50%ABBV: 50%
100% ABBV50/50100% WCRS
Portfolio after 10yr
$63.6K
Annual income
$13,023.09/yr
Blended yield
20.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WCRS
No analyst data
Altman Z
5.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WCRS buys
0
ABBV buys
0
No recent congressional trades found for WCRS or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWCRSABBV
Forward yield0.58%3.06%
Annual dividend / share$0.10$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR33.6%40.6%
Portfolio after 10y$24.9K$102.3K
Annual income after 10y$1,274.42$24,771.77
Total dividends collected$4.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WCRS vs ABBV ($10,000, DRIP)

YearWCRS PortfolioWCRS Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,778$78.13$11,550$430.00$772.00ABBV
2$11,638$105.14$13,472$627.96$1.8KABBV
3$12,594$141.75$15,906$926.08$3.3KABBV
4$13,667$191.53$19,071$1,382.55$5.4KABBV
5$14,883$259.53$23,302$2,095.81$8.4KABBV
6$16,278$352.88$29,150$3,237.93$12.9KABBV
7$17,900$481.90$37,536$5,121.41$19.6KABBV
8$19,814$661.63$50,079$8,338.38$30.3KABBV
9$22,116$914.47$69,753$14,065.80$47.6KABBV
10$24,938$1,274.42$102,337$24,771.77$77.4KABBV

WCRS vs ABBV: Complete Analysis 2026

WCRSStock

Western Capital Resources, Inc., through its subsidiaries, engages in the retail business in the United States. The company operates through Cellular Retail, Direct to Consumer, Manufacturing, and Consumer Finance segments. The Cellular Retail segment operates as an authorized retailer for Cricket Wireless selling cellular phones and accessories, ancillary services, and serving as a payment center for customers. This segment's Cricket retail stores offer various products and services, including cricket wireless service plans; cricket wireless plan upgrades, such Cricket International, individual country add-ons, Cricket Protect, and mobile hotspots; Cricket handsets and accessories; and a range of cellular accessories. The Direct to Consumer Segment is involved in the online and direct marketing distribution retail of live plants, seeds, holiday gifts, and garden accessories under the Park Seed, Jackson & Perkins, and Wayside Gardens brand names, as well as wholesale under the Park Wholesale brand. It also provides home improvement and restoration products under the Van Dyke's Restorers brand through online and mail catalogs. The Manufacturing segment offers mowers, safety shelters, agricultural accessories, timber management equipment, and string trimmers under the Swisher brand name. This segment also provides turn-key manufacturing services, such as powder coating, fabrication, assembly and distribution, welding, engineering and design, and contract manufacturing to third parties. The Consumer Finance segment offers sub-prime short-term uncollateralized non-recourse cash advance and installment loans, check cashing, and other money services; and owns and operates retail pawn stores. As of December 31, 2021, it owned and operated 229 cellular retail stores; 19 payday stores in Iowa, Kansas, North Dakota, and Wyoming; and 3 pawn stores in Nebraska and Iowa. The company was incorporated in 2001 and is headquartered in Omaha, Nebraska.

Full WCRS Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WCRS vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WCRS vs SCHDWCRS vs JEPIWCRS vs OWCRS vs KOWCRS vs MAINWCRS vs JNJWCRS vs MRKWCRS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.